Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total stock-based compensation expense	$ 1,904	$ 2,507	$ 3,786	$ 6,926
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	1,201	1,399	2,135	4,607
Cost of Revenue [Member]
Total stock-based compensation expense	44	31	80	54
Selling and Marketing Expense [Member]
Total stock-based compensation expense	387	455	790	899
General and Administrative Expense [Member]
Total stock-based compensation expense	1,214	1,674	2,292	5,262
Research and Development Expense [Member]
Total stock-based compensation expense	259	347	624	711
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	33	16	58	28
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	326	247	597	470
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	609	836	937	3,348
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	138	66	258	136
PAVmed Inc 2014 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	11	9	22	16
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	39	120	118	253
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	1	8	4	164
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 44	$ 97	$ 141	$ 192